Dr. Luiz Miguel Camargo is a Senior Commercialization Advisor at NobleReach Emerge, helping translate cutting-edge government-funded research into the commercial sector, with an emphasis on pharmaceutical and biotech projects.

Miguel has more than 20 years of experience in drug discovery, with much of his work being motivated by translating data sciences into real-world applications, He has led innovative data efforts at Merck, Novartis, and UCB working on translational medicine, target & biomarker discovery, lead identification & optimization, phenotypic screens, and efforts to better define disease using electronic medical records.

In addition to his role as computational biologist, Miguel has also led multidisciplinary drug discovery teams, as well as academic and industrial collaborations. At UCB, Miguel was responsible for identifying key and disruptive technologies by fostering partnerships with academic institutes, biotech companies, and venture funds. Miguel was deeply involved in building UCB’s research presence in the US and was responsible for building UCB’s Targeted Protein Degradation Platform that spans all three UCB research hubs (Belgium, UK, and US).

Miguel is a visiting scientist at the National Institutes of Biomedical Innovation, Health, and Nutrition,  in Osaka, Japan. He received his PhD in bioinformatics from the University of Cambridge, has several publications in leading journals, and is on the board of the Riverbend School in Natick, Massachusetts. He lives in Wellesley, MA.